Drugs like Ozempic, Wegovy, and Mounjaro seemingly transformed the weight loss industry overnight. Praised by celebrities, promoted heavily online and TV, and prescribed to millions of Americans, injectable GLP-1 receptor agonists have been highly effective at helping countless people shed significant weight.
But like other widely used pharmaceuticals, harmful side effects have resulted in thousands of lawsuits against Novo Nordisk and Eli Lilly, the manufacturers of the popular medications. This rapidly expanding litigation claims the weight loss drugs cause gastrointestinal injuries, including gastroparesis (stomach paralysis) and blockages, chronic vomiting, and sudden vision loss.
Given the sheer number of cases, those involving GI injuries associated with GLP-1 drugs were consolidated into multidistrict litigation (MDL) in February 2024. And in March, the litigation took an even more serious turn.
A wrongful death lawsuit was filed against Novo Nordisk. The plaintiff alleges his wife died from complications related to severe gastroparesis after taking Ozempic.
Wrongful Death Case Raises Stakes for GLP-1 Dangerous Pharmaceutical Litigation
On March 3, 2026, a wrongful death lawsuit was filed based on allegations that Ozempic caused a 76-year-old to develop gastroparesis, which escalated into a life-threatening medical emergency. The woman died on the way to the hospital, after suffering symptoms for days.
The family thought she had food poisoning, but it was a severe case of gastroparesis, a condition that causes the stomach to delay emptying. The woman eventually aspirated and died before getting to a local hospital.
The wrongful death case against Novo Nordisk claims the Ozempic drugmaker failed to adequately warn patients and physicians about the severity and possible long-term implications of gastroparesis associated with GLP-1 drugs.
The lawsuit is based on similar allegations to the widespread semaglutide (Wegovy, Ozempic, Rybelsus) and tirzepatide (Mounjaro) cases across the U.S. Thousands of plaintiffs are seeking compensation and accountability on the basis of failure to warn, negligence, and design defect.
But the wrongful death case may greatly affect all gastrointestinal injury lawsuits against manufacturers of Ozempic, Wegovy, and others; such cases often significantly increase pressure in mass tort litigation, including settlement negotiations, and greater public scrutiny surrounding pharmaceutical safety.
It also reflects a broader shift in the litigation. Plaintiffs are no longer focusing only on temporary nausea or vomiting; some are claiming GLP-1 weight loss drugs caused permanent harm, and now, at least one death.
Ozempic Gastroparesis MDL Update
The federal MDL involving gastrointestinal injuries associated with GLP-1 drugs continues to grow at a rapid pace. Centralized in the U.S. District Court for the Eastern District of Pennsylvania, it now includes over 3,600 lawsuits.
Symptoms and injuries alleged in the GLP-1 gastroparesis MDL range from stomach paralysis and intestinal obstruction to ileus, a disruption of intestinal muscle contractions that prevents food from moving through the digestive tract.
Plaintiffs in this GLP-1 weight loss mass tort allege manufacturers knew their drugs significantly delayed stomach emptying but failed to adequately warn consumers that complications could become severe or persistent.
While still in early stages, courts are already moving through consolidated pleading, scientific evidence disputes, and preparations for future bellwether trials.
One of the central legal arguments is whether Ozempic, Wegovy, and Mounjaro manufacturers sufficiently warned consumers and doctors that delayed gastric emptying could continue long after stopping the medication. Plaintiffs also argue that many users believed severe GI symptoms were normal side effects, rather than warning signs of serious injury.
GLP-1 Vision Loss MDL Growing
While gastroparesis lawsuits against GLP-1 drugmakers dominate headlines, a second major MDL is developing around vision loss associated with the medication.
In December 2025, federal courts created a separate MDL due to numerous lawsuits involving allegations that Ozempic, Wegovy, Saxenda, and Trulicity contributed to a serious condition causing vision loss. Often referred to as an “eye stroke”, non-arteritic anterior ischemic optic neuropathy (NAION) can cause sudden and irreversible blindness.
The GLP-1 vision loss MDL accelerated after multiple studies raised concerns about a possible association between semaglutide and NAION. One such study, published in the Journal of the American Medical Association Ophthalmology, analyzed data from 37.1 million adults with type 2 diabetes. Their findings showed a higher relative rate of NAION among semaglutide users.
The NAION semaglutide MDL has grown to 86 cases – roughly four times more than when the litigation was first consolidated last December.
Emergency Surgery Complications and GLP-1 Drugs
One of the most important – yet least discussed – issues involving GLP-1 weight loss drugs may have implications far beyond the lawsuits themselves: Surgery complications among patients taking diabetes weight loss medications.
Medical organizations have raised concerns that delayed stomach emptying caused by drugs like Ozempic and Wegovy can create dangerous complications during anesthesia and emergency surgery.
The American Society of Anesthesiologists previously advised many patients to stop weekly GLP-1 medications before surgery. This was due to how food remaining in the stomach may increase the risk of aspiration while under anesthesia.
Aspiration occurs when food or liquid is inhaled into the airway and lungs, and if it occurs when someone is sedated, serious complications could occur, including:
- Severe lung injury
- Pneumonia
- Respiratory failure
- Death
Updated guidance from multiple medical societies now recommend individualized assessments instead of blanket medication holds. And other countries are implementing practices to help avoid dangers for patients taking medications like Ozempic. In Australia, doctors delay surgery for patients on GLP-1 drugs over increased risk of pulmonary aspiration
The issue remains a growing concern in hospitals and surgical centers in the U.S. It could have major ramifications because millions of Americans now use Ozempic and similar drugs before colonoscopies, emergency and elective surgeries, and other procedures requiring sedation.
Ozempic Lawsuits Progressing
The GLP-1 weight loss drug litigation is rapidly evolving. Wrongful death allegations, gastroparesis claims, and expanding vision loss lawsuits are reshaping the legal battle surrounding some of America’s most popular medications.
Courts are moving closer toward bellwether trials in the MDL. At the same time, there’s mounting scientific evidence that further associates GLP-1 pharmaceuticals with increased risks of stomach paralysis, blindness, and surgical complications.
Other illnesses and conditions are being connected to these drugs, too. Ozempic has been linked to scurvy, thyroid issues, and kidney problems.
Now, with a wrongful death lawsuit filed against Novo Nordisk, its impact on existing and future litigation may be significant. Combined with existing lawsuits and the fact that millions of Americans are using these drugs for weight loss or to manage diabetes, the spotlight on and scrutiny of GLP-1 drugs is likely to increase.
